Nivolumab for the treatment of non-small cell lung cancer
Oubiña M, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32016001131
Spanish
Authors' recommendations:
The evidence on the effectiveness and safety of nivolumab as second line treatment for advanced non-small cell lung cancer, compared with docetaxel is of high quality. Nivolumab was associated with a longer overall survival of approximately three months and a lower incidence of adverse effects. No evidence was found for first line treatment. The clinical practice guidelines of the main oncology societies consider it a therapeutic alternative for the above mentioned population. In addition, the assessed U.S. private health sponsors cover it as second line treatment in these patients. Its high cost and the lack of local evidence on its cost-effectiveness limit the possibility of making a general recommendation on its coverage at health system level.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Nivolumab
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.